1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sage Impresses With Second Postpartum Depression Therapy

 
• By John Davis

Positive top-line Phase III data with Sage's second lead positive allosteric modulator at GABA receptors, SAGE-217, in postpartum depression continues to back the US biotech's approach to the devastating condition.  

Depression
Postpartum depression can be devastating for mothers and their families • Source: Shutterstock

The value of Cambridge, Mass.-based SAGE Therapeutics Inc.'s shares surged by 50% on Jan. 7 as the CNS-focused biotech released positive top-line Phase III results for its second lead compound, the orally administered SAGE-217, in postpartum depression, and the company's management presented an update of its commercial strategy at the J. P. Morgan Healthcare conference.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.